Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background

Chronic coronary syndromes (CCS) is a common clinical condition that increases the risk of cardiovascular events at any time. Tongxinluo capsules (TXL) are widely used in China for treating CCS.

Objectives

To systematically evaluate the therapeutic effects and safety of adding TXL to Western medical treatment (WM) for CCS.

Methods

We searched PubMed, Cochrane Library, CNKI, VIP, and Wanfang databases up to August 2024 for randomized controlled trials (RCTs) investigating the therapeutic effects and safety of combining TXL with WM compared to WM alone for CCS. Data analyses were conducted using RevMan 5.4 software.

Results

Twenty studies involving 2091 participants were identified. Evidence supports the use of TXL plus WM for reducing angina frequency

SUBMITTER: Liang SB 

PROVIDER: S-EPMC11753206 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature